Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06593106 · ClinicalTrials.gov registry record · NA
Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial
A NA study of Stage II Lung Cancer and Stage I Lung Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06593106: Recruiting NA study of Stage II Lung Cancer and Stage I Lung Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
NCT06593106 is a NA study of Stage II Lung Cancer and Stage I Lung Cancer that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 30 participants, below the 102-participant average among 3 other Stage II Lung Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06593106, a NA study of Stage II Lung Cancer and Stage I Lung Cancer, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies side effects and best treatment time of cryodevitalization in treating patients with early stage (stage I or stage II) lung cancer. Cryodevitalization is a type of cryosurgery that uses a flexible probe (cryoprobe) to kill tumor cells by freezing them. It is delivered at the time of standard diagnostic robotic bronchoscopy. Using cryodevitalization may be safe, tolerable and/or effective in treating patients with early stage lung cancer.
Primary Outcome
Will implement a modified Toxicity Probability Interval design. Each dose will be modeled using a Beta-Binomial model with the prior distribution, Beta (1,1). For each dose level, a 95% credible interval for the toxicity probability will be computed.
Conditions Studied
Interventions
- PROCEDURE Chest Radiography
- PROCEDURE Cryosurgery
- PROCEDURE Resection
- PROCEDURE Robotic Bronchoscopy
- PROCEDURE Bronchoscopy with Biopsy
Study Locations (1)
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2026-08-31 |
| Phase | NA |
What NCT06593106 shows while recruiting
NCT06593106 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 102-participant average among 3 other Stage II Lung Cancer trials with a reported enrollment target (71% lower).
The record links to 2 conditions, with Stage II Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Chest Radiography is the first listed.
NCT06593106 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06593106 about?
NCT06593106 is a clinical study titled "Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial". This clinical trial studies side effects and best treatment time of cryodevitalization in treating patients with early stage (stage I or stage II) lung cancer. Cryodevitalization is a type of cryosurgery that uses a flexible probe (cryoprobe) to kill tumor cells by freezing them. It is delivered at ...
What is the current status of trial NCT06593106?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-09-27. Estimated completion is 2026-08-31.
What conditions does trial NCT06593106 study?
This clinical trial studies the following conditions: Stage II Lung Cancer, Stage I Lung Cancer.
What interventions are being tested in trial NCT06593106?
The interventions under investigation include: Chest Radiography (PROCEDURE), Cryosurgery (PROCEDURE), Resection (PROCEDURE), Robotic Bronchoscopy (PROCEDURE), Bronchoscopy with Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT06593106?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06593106 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI